He Kang, Zheng Jingying, Zhang Tingyu, Lv Hao, Wang Kai, Wang Zeyu, Wang Longyun, Wu Shan, Zhao Lijing
Department of Rehabilitation, School of Nursing, Jilin University, Changchun, 130021, China.
The Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, 130041, Jilin, China.
Eur J Med Res. 2025 Mar 15;30(1):174. doi: 10.1186/s40001-025-02293-0.
The rise in endometrial cancer rates globally calls for advanced diagnostic methods and new biomarkers. CPA4, known for its role in cancer development, has not yet been studied in relation to endometrial cancer, making it a promising research avenue.
We analyzed CPA4's mRNA expression using data from TCGA and GEO databases and validated these findings with 116 clinical samples through immunohistochemical analysis. The Ishikawa and Hec-1-A cell lines were used to examine CPA4's functionality. In addition, we conducted correlation analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and survival analysis to understand CPA4's role in endometrial cancer prognosis. A nomogram model was developed for clinical prognostic predictions.
CPA4 is significantly overexpressed in endometrial cancer, correlating with tumor progression and poor prognosis. Overexpression is linked to crucial functions, such as mitosis and cell cycle. Reducing CPA4 in cell lines inhibited tumor growth and spread. Kaplan-Meier plots and Cox regression analysis confirmed CPA4's significance in prognosis, with our predictive model showing high accuracy.
CPA4 emerges as a vital biomarker for diagnosing and prognosing endometrial cancer, presenting a novel pathway for research and clinical application. The study highlights its potential as a clinical tool, paving the way for improved patient management and treatment strategies in endometrial cancer.
全球子宫内膜癌发病率的上升需要先进的诊断方法和新的生物标志物。CPA4因其在癌症发展中的作用而闻名，但尚未针对子宫内膜癌进行研究，这使其成为一个有前景的研究方向。
我们使用来自TCGA和GEO数据库的数据分析了CPA4的mRNA表达，并通过免疫组织化学分析用116个临床样本验证了这些结果。使用Ishikawa和Hec-1-A细胞系来检测CPA4的功能。此外，我们进行了相关性分析、基因本体论（GO）、京都基因与基因组百科全书（KEGG）、基因集富集分析（GSEA）和生存分析，以了解CPA4在子宫内膜癌预后中的作用。开发了一个列线图模型用于临床预后预测。
CPA4在子宫内膜癌中显著过表达，与肿瘤进展和不良预后相关。过表达与有丝分裂和细胞周期等关键功能有关。在细胞系中降低CPA4可抑制肿瘤生长和扩散。Kaplan-Meier曲线和Cox回归分析证实了CPA4在预后中的重要性，我们的预测模型显示出高准确性。
CPA4成为诊断和预测子宫内膜癌的重要生物标志物，为研究和临床应用提供了一条新途径。该研究突出了其作为临床工具的潜力，为改善子宫内膜癌患者的管理和治疗策略铺平了道路。
